These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23777222)

  • 1. Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.
    Dacosta Byfield S; Yu E; Morlock R; Evans D; Teitelbaum A
    J Med Econ; 2013 Aug; 16(8):1071-81. PubMed ID: 23777222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
    Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
    Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing medical care by disease phase in metastatic colorectal cancer.
    Song X; Zhao Z; Barber B; Gregory C; Schutt D; Gao S
    Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP20-5. PubMed ID: 21711074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
    Kiss I; Bortlicek Z; Melichar B; Poprach A; Halamkova J; Vyzula R; Dusek L; Buchler T
    Anticancer Res; 2014 Feb; 34(2):949-54. PubMed ID: 24511038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Service setting impact on costs for bevacizumab-treated oncology patients.
    Engel-Nitz NM; Yu EB; Becker LK; Small A
    Am J Manag Care; 2014 Nov; 20(11):e515-22. PubMed ID: 25730350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
    Rautenberg T; Siebert U; Arnold D; Bennouna J; Kubicka S; Walzer S; Ngoh C
    J Med Econ; 2014 Feb; 17(2):99-110. PubMed ID: 24215550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
    Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
    Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
    J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
    Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
    Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.
    De Stefano A; Carlomagno C; Pepe S; Bianco R; De Placido S
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1207-13. PubMed ID: 21409384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
    Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
    J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.